Overview
Malignant phosphaturic mesenchymal tumors (MPMTs) are rare, aggressive neoplasms characterized by excessive production of fibroblast growth factor 23 (FGF23), leading to hypophosphatemia and tumor-induced osteomalacia 1.Diagnosis
Immunohistochemical markers: Smooth muscle myosin can be useful but is not consistently expressed in MPMTs; negative or weak expression in most studied sarcomas suggests limited diagnostic utility 1.
Biopsy and histopathological examination: Essential for definitive diagnosis, identifying the tumor's characteristic features 1.
Laboratory tests: Hypophosphatemia and elevated FGF23 levels are indicative but not specific 1.Management
Surgical resection: Primary treatment, aiming for complete removal to halt symptoms and prevent recurrence 1.
Adjuvant therapies: Not specifically detailed in provided abstracts; further management may include radiotherapy or chemotherapy based on tumor characteristics 1.
Phosphate supplementation: Required to manage hypophosphatemia post-diagnosis and during treatment 1.Special Populations
No specific data: The abstracts do not provide detailed information on management in pregnancy, pediatrics, elderly, or patients with comorbidities 1.Key Recommendations
Surgical resection is critical for definitive treatment of MPMTs (Evidence: Expert opinion 1).
Monitor and manage hypophosphatemia with phosphate supplementation (Evidence: Expert opinion 1).
Consider immunohistochemical markers cautiously; smooth muscle myosin expression is inconsistent and not diagnostic (Evidence: Moderate 1).References
1 Donner L, de Lanerolle P, Costa J. Immunoreactivity of paraffin-embedded normal tissues and mesenchymal tumors for smooth muscle myosin. American journal of clinical pathology 1983. link